MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer
Authors:
Open Access
- 2 April 2022
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 127 (2) , 249-257
Abstract
Background: To analyse the performance of multicentre pre-treatment MRI-based radiomics (MBR) signatures combined with clinical baseline characteristics and neoadjuvant treatment modalities to predict complete response to neoadjuvant (chemo)radiotherapy in locally advanced rectal cancer (LARC). Methods: Baseline MRI and clinical characteristics with neoadjuvant treatment modalities at four centres were collected. Decision tree, support vector machine and five-fold cross-validation were applied for two non-imaging and three radiomics-based models’ development and validation. Results: We finally included 674 patients. Pre-treatment CEA, T stage, and histologic grade were selected to generate two non-imaging models: C model (clinical baseline characteristics alone) and CT model (clinical baseline characteristics combining neoadjuvant treatment modalities). The prediction performance of both non-imaging models were poor. The MBR signatures comprising 30 selected radiomics features, the MBR signatures combining clinical baseline characteristics (CMBR), and the CMBR incorporating neoadjuvant treatment modalities (CTMBR) all showed good discrimination with mean AUCs of 0.7835, 0.7871 and 0.7916 in validation sets, respectively. The three radiomics-based models had insignificant discrimination in performance. Conclusions: The performance of the radiomics-based models were superior to the non-imaging models. MBR signatures seemed to reflect LARC’s true nature more accurately than clinical parameters and helped identify patients who can undergo organ preservation strategies.Keywords
This publication has 55 references indexed in Scilit:
- Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal CancerDiseases of the Colon & Rectum, 2013
- Clinical Prediction of Pathological Complete Response After Preoperative Chemoradiotherapy for Rectal CancerDiseases of the Colon & Rectum, 2013
- Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trialThe Lancet Oncology, 2012
- Radiomics: Extracting more information from medical images using advanced feature analysisEuropean Journal of Cancer, 2012
- Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trialRadiotherapy and Oncology, 2012
- Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imagingRadiotherapy and Oncology, 2011
- Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 StudyJournal of Clinical Oncology, 2010
- Decision Curve Analysis: A Novel Method for Evaluating Prediction ModelsMedical Decision Making, 2006
- Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancerHistopathology, 2005